ADVERTISEMENT

New hypertension guidelines: One size fits most?

Cleveland Clinic Journal of Medicine. 2014 March;81(3):178-188 | 10.3949/ccjm.81a.14003
Author and Disclosure Information

ABSTRACTThe report of the panel appointed to the eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) is more evidence-based and focused than its predecessors, outlining a management strategy that is simpler and, in some instances, less aggressive. It has both strengths and weaknesses.

KEY POINTS

  • JNC 8 focuses on three main questions: when to begin treatment, how low to aim for, and which antihypertensive medications to use. It does not cover many topics that were included in JNC 7.
  • In patients age 60 or older, JNC 8 recommends starting antihypertensive treatment if the blood pressure is 150/90 mm Hg or higher, with a goal of less than 150/90.
  • For everyone else, including people with diabetes or chronic kidney disease, the threshold is 140/90 mm Hg, and the goal is less than 140/90.
  • The recommended classes of drugs for initial therapy in nonblack patients without chronic kidney disease are thiazide-type diuretics, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), although the last two classes should not be used in combination.
  • For black patients, the initial classes of drugs are diuretics and calcium channel blockers; patients with chronic kidney disease should receive an ACE inhibitor or ARB.

Recommendation 1: < 150/90 for those 60 and older

In the general population age 60 and older, the JNC 8 recommends starting drug treatment if the systolic pressure is 150 mm Hg or higher or if the diastolic pressure is 90 mm Hg or higher, and aiming for a systolic goal of less than 150 mm Hg and a diastolic goal of less than 90 mm Hg.

Strength of recommendation—strong (grade A).

Comments. Of all the recommendations, this one will probably have the greatest impact on clinical practice. Consider a frail 70-year-old patient at risk of falls who is taking two antihypertensive medications and whose blood pressure is 148/85 mm Hg. This level would have been considered too high under JNC 7 but is now acceptable, and the patient’s therapy does not have to be escalated.

The age cutoff of 60 years for this recommendation is debatable. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS)7 included patients ages 60 to 85 (mean age 74) and found no difference in outcomes comparing a goal systolic pressure of less than 140 mm Hg (this group achieved a mean systolic pressure of 135.9 mm Hg) and a goal systolic pressure of 140 to 160 mm Hg (achieved systolic pressure 145.6 mm Hg).

Similarly, the Valsartan in Elderly Isolated Systolic Hypertension (VALISH) trial8 included patients ages 70 to 84 (mean age 76.1) and found no difference in outcomes between a goal systolic pressure of less than 140 mm Hg (achieved systolic pressure 136.6 mm Hg) and a goal of 140 to 150 mm Hg (achieved systolic pressure 142 mm Hg).

The Hypertension in the Very Elderly Trial (HYVET)9 found lower rates of stroke, death, and heart failure in patients age 80 and older when their systolic pressure was less than 150 mm Hg.

While these trials support a goal pressure of less than 150 mm Hg in the elderly, it is unclear whether this goal should be applied beginning at age 60. Other guidelines, including those recently released jointly by the American Society of Hypertension and the International Society of Hypertension, recommend a systolic goal of less than 150 mm Hg in people age 80 and older—not age 60.10

The recommendation for a goal systolic pressure of less than 150 mm Hg in people age 60 and older was not unanimous; some panel members recommended continuing the JNC 7 goal of less than 140 mm Hg based on expert opinion, as they believed that the evidence was insufficient, especially in high-risk subgroups such as black people and those with cerebrovascular disease and other risk factors.

A subsequent minority report from five panel members discusses in more detail why they believe the systolic target should be kept lower than 140 mm Hg in patients age 60 or older until the risks and benefits of a higher target become clearer.11

Corollary recommendation: No need to down-titrate if lower than 140

In the general population age 60 and older, dosages do not have to be adjusted downward if the patient’s systolic pressure is already lower than 140 mm Hg and treatment is well tolerated without adverse effects on health or quality of life.

Strength of recommendation—expert opinion (grade E).

Comments. In the studies that supported a systolic goal lower than 150 mm Hg, many participants actually achieved a systolic pressure lower than 140 mm Hg without any adverse events. Trials that showed no benefit from a systolic goal lower than 140 mm Hg were graded as lower in quality. Thus, the possibility remains that a systolic goal lower than 140 mm Hg could have a clinically important benefit. Therefore, medications do not have to be adjusted so that blood pressure can “ride up.”

For example, therapy does not need to be down-titrated in a 65-year-old patient whose blood pressure is 138/85 mm Hg on two medications that he or she is tolerating well. On the other hand, based on Recommendation 1, therapy can be down-titrated in a 65-year-old whose pressure is 138/85 mm Hg on four medications that are causing side effects.

Recommendation 2: Diastolic < 90 for those younger than 60

In the general population younger than 60 years, JNC 8 recommends starting pharmacologic treatment if the diastolic pressure is 90 mm Hg or higher and aiming for a goal diastolic pressure of less than 90 mm Hg.

Strength of recommendation—strong (grade A) for ages 30 to 59, expert opinion (grade E) for ages 18 to 29.

Comments. The panel found no evidence to support a goal diastolic pressure of 80 mm Hg or less (or 85 mm Hg or less) compared with 90 mm Hg or less in this population.

It is reasonable to aim for the same diastolic goal in younger persons (under age 30), given the higher prevalence of diastolic hypertension in younger people.

Recommendation 3: Systolic < 140 for those younger than 60

In the general population younger than 60 years, we should start drug treatment at a systolic pressure of 140 mm Hg or higher and treat to a systolic goal of less than 140 mm Hg.

Strength of recommendation—expert opinion (grade E).

Comments. Although evidence was insufficient to support this recommendation, the panel decided to keep the same systolic goal for people younger than 60 as in the JNC 7 recommendations, for the following two reasons.

First, there is strong evidence supporting a diastolic goal of less than 90 mm Hg in this population (Recommendation 2), and many study participants who achieved a diastolic pressure lower than 90 mm Hg also achieved a systolic pressure lower than 140. Therefore, it is not possible to tease out whether the outcome benefits were due to lower systolic pressure or to lower diastolic pressure, or to both.

Second, the panel believed the guidelines would be simpler to implement if the systolic goals were the same in the general population as in those with chronic kidney disease or diabetes (see below).

Recommendation 4: < 140/90 in chronic kidney disease

In patients age 18 and older with chronic kidney disease, JNC 8 recommends starting drug treatment at a systolic pressure of 140 mm Hg or higher or a diastolic pressure of 90 mm Hg or higher and treating to a goal systolic pressure of less than 140 mm Hg and a diastolic pressure of less than 90 mm Hg.

Chronic kidney disease is defined as either a glomerular filtration rate (estimated or measured) less than 60 mL/min/1.73 m2 in people up to age 70, or albuminuria, defined as more than 30 mg/g of creatinine at any glomerular filtration rate at any age.

Strength of recommendation—expert opinion (grade E).

Comments. There was insufficient evidence that aiming for a lower goal of 130/80 mm Hg (as in the JNC 7 recommendations) had any beneficial effect on cardiovascular, cerebrovascular, or mortality outcomes compared with 140/90 mm Hg, and there was moderate-quality evidence showing that treatment to lower goal (< 130/80 mm Hg) did not slow the progression of chronic kidney disease any better than a goal of less than 140/90 mm Hg. (One study that did find better renal outcomes with a lower blood pressure goal was a post hoc analysis of the Modification of Diet in Renal Disease study data in patients with proteinuria of more than 3 g per day.12)

We believe that decisions should be individualized regarding goal blood pressures and pharmacologic therapy in patients with chronic kidney disease and proteinuria, who may benefit from lower blood pressure goals (<130/80 mm Hg), based on low-level evidence.13,14 Risks and benefits should also be weighed in considering the blood pressure goal in the elderly with chronic kidney disease, taking into account functional status, comorbidities, and level of proteinuria.